ASCO 2024

Prognostic value of ctDNA in therapeutic strategies; Endocrine therapy in ER-low BC

Immunotherapy makes a difference in survival in eTNBC

The search for predicitve biomarkers continues

Adjuvant endocrine therapy for ER-low EBC

Personalized neoadjuvant therapy for high-risk breast cancer patients

AI for the prediction of disease progression

Avelumab in early TNBC

Advantage for node-negative patients

ctDNA important for HR+ eBC?

Ribociclib is also effective in N0 HR+/HER2− EBC

ctDNA analysis in monarchE

Avelumab nel TNBC precoce

Improvement for firstline treatment for patients with endocrine resistance

Expanding T-DxD use to HER2 ultra-low - the success story continues

Reassuring and clarifying new data for CDK4/6 inhibitors

One step closer to chemo-free therapy for HR+/HER2+ patients

Responder premenopausal

Systemic therapy of HER2+ patients with brain metastases

Leptomeningeal metastases in HER2+ mBC

ER-low: endocrine therapy necessary after all?

Eribulin, Trastuzumab, Pertuzumab in 1stL HER2+ mBC

New data on the omission of chemotherapy in young patients

Heterogenity of ER+ disease

Triple positive mBC - chemotherapy unnecessary?

Is there still a place for endocrine therapy in HER2+ BC

Novel ADC-ICI combination therapy

Decreasing SG related toxicity with profilatic G-CFS

T-DXD continues its impressive track record for MBC patients

Important OS benefit with T-Dxd in HER2+ mBC

Sacituzumab tirumotecan - a new powerful ADC for advanced TNBC

The ADC revolution continues - ctDNA takes the next step in tumor characterization

Expanding use of T-DxD in HER2low and HER2 ultra-low MBC patients

HER2+ mBC 1stL T-Dxd

Ultra low - ultra good?

Broaden T-DXD as therapy standard for HER2low and ultra-low MBC

Chemo-free regimen in HER2+ luminal breast cancer

CDK4/6i effective in premenopausal patients as well

Chemo-free, CDK4/6 inhibitor-based combination active in HR+/HER2+ PAM50-luminal advanced breast cancer

CDK4/6 rechallenge

Treatment beyond progression for CDK 4/6i

Endocrine therapy with Palbociclib + Trastuzumab

First-line inavolisib/placebo + palbociclib + fulvestrant preferred in patients with PIK3CA HR+ HER2- advanced breast cancer

Already more in the 1stL?

INAVO120 - updated results

Sacituzumab tirumotecan – nowy aktywny koniugat w leczeniu zaawansowanego raka trójujemnego

Le traitement endocrinien a-t-il encore sa place dans la CB HER2+ ?

La révolution de l'ADC se poursuit / ctDNA franchit une nouvelle étape dans la caractérisation des tumeurs

Disminución de la toxicidad relacionada con la OS con G-CSF y loperamide profiláctica

Regime senza chemioterapia nel carcinoma mammario luminoso HER2+

Importante beneficio en la supervivencia global con TDxD en el CMm HER2+

INAVO120: risultati aggiornati

CDK4/6 rechallenge

Leczenie bez chemioterapii, oparte na inhibitorze CDK4/6 aktywne w zaawansowanych rakach HR+/HER2+ o fenotypie luminalnym wg PAM50

Espansione dell'uso di T-DxD nelle pazienti con carcinoma mammario metastatico HER2-low e HER2 ultra-low

C'è ancora posto per la terapia endocrina nel BC HER2+?

PSMA-PET CT: Ready for clinical practice or a PROMISE for the future?

Focus on Quality of Life

Interesting data - but not practice changing

Is the metformin story over? How to treat HFNS symptomatology?

EMBARK: Quality of Life

mCRCP CYCLONE 2 study

Important QoL data

mCRPC: Who benefits from which measures?

Unlocking Insights: The ALLIANCE Trial redefining Prognostic Models in Metastatic Prostate Cancer

Exploring the CHAARTED TRIAL: Optimizing Treatment Strategies in Metastatic Prostate Cancer

ARASENS Post hoc analysis: Therapy after progression

Unveiling the Potential: PSMA-PET in Prostate Cancer Staging - Insights from the PROMISE TRIAL

EMBARK demonstrates the importance of HRQoL benefit in both combination and monotherapy arms

The evolving role of PSMA-PET with new agents

Radionukleotides - the next step forward

Deciphering EMBARK: Exploring Enzalutamide's Impact on Prostate Cancer Progression and Quality of Life

RCT in mCRPC

EV-Pembro shows consistent outcome - caution with subset analyses

Perioperative treamtent in MIBC - new data for the use of sacituzumab govitecan

Modified FOLFIRINOX therapy as a good option for urachus carcinoma

What to do with Cis Gem Nivo?

Preoperative use of sacituzumab govitecan

ASCO 2024: Time for the rare GU tumors?

MI-UC - News from EVP standard

Treatment of urachal carcinoma

Quality of life not affected by i. v. Pembro

Effect of an immune diet on the outcome after radical cystectomy

Biomarkers and long-term outcomes in pts with low tumor burden

ctDNA as a biomarker in metastatic bladder cancer

The Role of Topoisomerase Inhibitors in the preoperative setting of MIBC: The story has just begun

ASCO24: Bladder cancer highlights

Interim analysis of the SURE-01/02 study

The future of sacituzumab govitecan

El futuro de sacituzumab govitecan

ASCO24: Bladder cancer highlights

El papel de los inhibidores de topoisomerasa en el contexto perioperatorio del cancer de vejiga musculo infiltrante: la historia acaba de empezar

ASCO 2024: momento para los tumores GU poco frequentes?

Biomarcadores y resultados a largo plazo en pacientes con baja carga tumoral

Supportive real-world data from German research platform CARAT

Evaluating risk criteria and monotherapy in mRCC

Advancing our understanding of biological mechanisms and the quest for the Ideal biomarker - Part 1

Advancing Our Understanding of Biological Mechanisms and the Quest for the Ideal Biomarker - Part 2

Combination is superior to monotherapy - how do we translate the results into clinical practice?

NIVO+CABO: significantly longer therapy-free time

New IMDC risk group - very favorable

New HIF inhibitor in clear cell RCC

KIM-1 - old wine in new bottles

The never ending saga of biomarkers

Biomarker analysis of KN426 & CLEAR

Belzutifan in earlier lines in advanced ccRCC

Metastasized chromophobe RCC

Combination therapies for chromophobe renal cell carcinoma are clearly superior

Another breakthrough perioperative

DFF332 a novel HIF inhibitor

The search of the ideal biomarker in advanced renal cell carcinoma: The Sisyphus myth?

KIM-1: Will have a major impact

Adjuvant KIM-1 as prognostic & predictive biomarker

Treatment of favorable prognosis mRCC patients: additional data to support treatment decisions

nccRCC

La busqueda del marcador ideal en el cancer renal avanzado: el mito de Sísifo?

Tratamiento del cancer renal avanzado de pronostico favorable: datos adicionales para ayudar en la decision clinica

End of the story in EGFRm disease?

Adjuvant therapy: how to identify patients who will benefit

Gamechanger in EGFR-mutated NSCLC

4-year efficacy of Keynote-799 and ctDNA

ctDNA predicts outcome in patients treated with osimertinib

CheckMate 816: 4-year update

Stadium III EGFR+: now permanently Osimertinib?!

Perioperative chemotherapy and N2 status

Osimertinib improves PFS in stage III

4y follow-up of CheckMate 816

Liquid biopsy in curative situation

Confirmed efficacy of periop IO in N2 R-NSCLC

Early change in SOC in EGFR+ LD-NSCLC

Cambio temprano en el tratamiento estándar del EGFR+ LD-NSCLC

Le traitement adjuvant par osimertinib apres CTRT : changement de donne dans le cas du CBNPC muté EGFR

4y follow-up de CheckMate 816

Update for EGFR-positive NSCLC

TROP2-targeting ADCs: where a we heading?

KRAS in NSCLC - a lot to come

Lorlatinib with extraordinary data in ALK + NSCLC

ASCO 2024 highlights

BAY2927088 - Promising Her2-Inhibitor in NSCLC

ALK+ NSCLC - CROWN revisited

EGFR+ NSCLC - amivantamab-based combination therapy

KRASG12C - the story continues

Subcut amivantamab - the future

Lorlatinib convincing in ALK mutation 1st line

Confirmed efficacy of adagrasib in KRASG12C

The end for local therapy for oligometastatic disease

Telehealth is just as effective as a face-to-face visit in early palliative care

Confirmed efficacy in PD-L1 negativity - CheckMate 9LA

KRAS building on single agent therapy

Adagrasib for KRASG12C mutation 2nd line

ADCs - moving landscapes. Subgroups remain to be defined.

La télésanté est aussi efficace qu'une consultation face a face dans les soins palliatifs précoces

ASCO 2024 highlights

KRASG12C - het verhaal gaat verder

Het einde van lokale therapie voor oligometastatische ziekte

ASCO 2024 highlights

BAY297088 - Inhibiteur Her2-Inhibitor dans le NSCLC

Redefining SOC in LD-SCLC: Durvalumab as consolidation therapy

Maintenance with durvalumab is the new SOC after chemo/radio therapy for LD-SCLC

Finally, change for LS-SCLC

Tarlatamab shows activity in patients with brain metastasis

LD-SCLC: What´s about PCI?

New SoC for LD-SCLC

Le traitement d'entretien avec le durvalumab est le nouveau SOC après la chimio/radiothérapie pour le carcinomes à petites cellules en forme limitée

Tot slot, verandering voor LS-SCLC

Unexpected results; which subgroup could benefit from atezolizumab?

Harsh to beat

Chemo-immuno in mesothelioma - update

Difícil de superar

10 years follow up - immunotherapy for BRAF-mutated melanoma

Personalized mRNA-vaccination: Practice changer of the future?

Is the triplet ready for phase 3?

Is adjuvant treatment still standard in macroscopic, resectable stage III melanoma?

Is the induction treatment the new strategy for selected patient group?

Stimulating new combination of two antibody-cytokine fusions

Survival data for TT with dabrafenib and trametinib

Longterm survival after adjuvant targeted therapy

Lentigo maligna therapy

mRNA vaccine plus pembrolizumab in adjuvant therapy

A new triplet for metastatic melanoma

Progress in neoadjuvant therapy with IO

Neoadjuvant intratumoral therapy with Daromun in metastatic melanoma

Intralesional therapy with Daromun

Identifying patients with longterm benefits during tebentafusp in mUM

Impactful studies from ASCO 24 II: Combi-AD

Impactful studies from ASCO 24 III: Cell-therapy

3-year update on mRNA vaccines in melanoma

Consolidation of the use of IO in clinically detectable stage III melanoma

Promising activity of brenetafusp in PD-L1 refractory melanoma

TIL therapy for metastatic melanoma

New oncolytic immunotherapy (RP1) after PD-1 failure

Impactful studies from ASCO 24 I: NADINA

Emerging rescue therapies for PD1 refractory melanoma

Neoadjuvant immunotherapy treatment for melanoma

Vaccine in combination with nivolumab for PDL1 resistance

Triple checkpoint blockade - a new approach?

No differences in PFS between the two study arms

A new therapy benchmark for brain-met melanoma patients

Promising Results: Triple combination therapy in advanced melanoma

Adjuvant therapy with dabrafenib and trametinib - final results after 4 years

Risultati promettenti: Tripla terapia di combinazione nel melanoma avanzato

No hubo diferencias en la PFS entre los dos brazos del estudio

Consolidación del uso de IO en melanoma en estadio III clínicamente detectable

Prometedora actividad de brenetafusp en melanoma refractario a PD-L1

Encouraging developmental IO-options

New therapeutic approaches: Get over PD1 resistances?

New insights in localized HNSCC

New perspectives in HPV+ r/m HNSCC

New MOA in r/m HNSCC

Clear cell carcinomas benefit from IO therapy

New idea: anti-digest for EC?

De-escalation in ovarian cancer?